Autonomic Reactivity and Personalized Neurostimulation
Recruiting · Not applicable · NCT06863207
Conditions: Functional Gastrointestinal Disorders (FGIDs), Cyclic Vomiting Syndrome, Functional Dyspepsia, Dysautonomia
At a glance
- Research payments reported, 2025
- $15,000
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- Medical College of Wisconsin (with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))
- Tested
- Percutaneous electrical nerve field stimulation (device), Hypnotherapy (behavioral)
- Dates
- Started 2025-01-24; completion 2029-06
- Results posted
- Not yet
Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology. Many patients manifest comorbidities suggesting an underlying autonomic nervous system (ANS) dysregulation (palpitations, dizziness, cognitive dysfunction). Unfortunately, due to common features of anxiety and visceral hyperreactivity and lack of obvious pathology, children with DGBI are frequently diagnosed with psychosomatic or 'beni…
From ClinicalTrials.gov, last updated 2026-02-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Neuraxis, Inc. reported $15,000 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $15,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.